Download Program CESORO-3

3rd Central European Symposium on Radiation Oncology
Technological and Biological Sunrise for Radiation Oncology
6-8.10.2016, Ustroń, Poland
Scientific Program
Thursday; 6th October 2016
19:00 –
Welcome Dinner
Friday; 7th October 2016
9:00 – 9:10
Opening Ceremony
9:10 – 11:30
Radiation Biology and Biomarkers (Part 1)

Michael Story (UTSW, Dallas): Challenges to the implementation of predictive biomarkers in
radiation oncology [30’]

Annett Linge (TUD, Dresden): Biomarkers for individualisation of radiochemotherapy in
HNSCC – the German DKTK experience [30’]

Katalin Lumniczky (NRIRR, Budapest): Radiochemotherapy induced phenotypical changes in
peripheral blood cells of cancer patients [30’]

Tomasz Rutkowski (IO, Gliwice): Circulating free HPV DNA as a prognostic marker in patients with
HPV-related head and neck cancer treated with radiotherapy or radio-chemotherapy [20’]

Piotr Widłak (IO, Gliwice): Inflammation related to acute radiation toxicity is the major factor affecting
molecular changes observed in blood of cancer patients treated with radiotherapy [20’]

Łukasz Boguszewicz (IO, Gliwice): 1H NMR based metabolomics in monitoring of the head and
neck cancer treatment toxicity [10‘]
11:30 – 12:00
Coffee Break (and poster viewing)
12:00 – 14:00
Particle Therapy (Part 1)

Marco Schwarz (Trento Hospital, Trento): How can protons improve radiation oncology? [30’]

Roberto Orecchia (CNAO, Pavia): Hadrontherapy with heavy ions: current indications and
future perspectives [30’]

Thomas Bjork Errickson (Skandion Clinic, Uppsala): One year of clinical practice at the
Skandion Clinic - ups and downs [30’]

Jiri Kubes (PTC, Prague): Radiochemotherapy with protons [30’]
14:00 – 15:00
Lunch (and poster viewing)
15:00 – 18:30 Contemporary Radiotherapy and Personalized Treatment (Part 1)

Hak Choy (UTSW, Dallas): I-SABR [30’]

Rafał Dziadziuszko (GUMed, Gdańsk): Stage III NSCLC – how to individualize definitive radiochemotherapy? [20’]

Krzysztof Składowski (IO, Gliwice): Continuous, chronological monitoring of selected biomarkers
can predict the outcome of SCCHN patients treated by RT with or without chemotherapy [20’]

Bogusław Maciejewski (IO, Gliwice): Volumetric staging and molecular and image guided
radiotherapy for H&N cancer [20’]
16:30 – 17:00
Coffee Break (and poster viewing)

Rafał Suwiński (IO, Gliwice): Immunotherapy and the abscopal effect of radiotherapy [20’]

Rafał Tarnawski (IO, Gliwice): Molecular imaging of breast cancer heterogeneity [20’]

Joanna Polańska (SUT, Gliwice): Computer aided segmentation of brain tumour in MRI apparent
diffusion coefficient (ADC) maps [20’]

Leszek Miszczyk (IO, Gliwice): CyberKnife (CK) radioablation for prostate cancer patients – early
results of 400 patients treatment [20’]

Małgorzata Wyduba & Wojciech Majewski (IO, Gliwice): The efficacy of palliative radiotherapy for
patients with lung cancer: the QoL analysis [10’].
19:30 –
Conference Dinner
Saturday; 8th October 2016
9:00 – 11:30
Contemporary Radiotherapy and Personalized Treatment (Part 2)

Asal Rahimi (UTSW, Dallas): S-PBI (Stereotactic Partial breast Irradiation) [30’]

Rafał Tarnawski (IO, Gliwice): Imaging of cervical cancer recurrence (lecture sponsored by Roche)
[20’]

Daria Handkiewicz-Junak (IO, Gliwice): Consolidation treatment with somatostatin analogues after
radiopeptide therapy [10‘]

Jolanta Krajewska (IO, Gliwice): Multikinase inhibitors in patients with radioiodine-refractory thyroid
cancer – the evaluation of treatment tolerance on the basis of 10-year experience [10’].

Agata Celejewska (IO, Gliwice): 10-years of CBS and IORT (INTRABEAM) combined with
postoperative EXRT for early breast cancer: incidence and kinetics of local recurrence and distant
metastases [10’]

Piotr Wojcieszek (IO, Gliwice): High-dose-rate brachytherapy for recurrent prostate cancer –
effective tool for the individualized treatment [10’]

Aleksandra Napieralska (IO, Gliwice): Craniospinal irradiation – experience of Radiotherapy
Department in Gliwice [10’]

Dorota Gabryś (IO, Gliwice): Cardiac toxicity after breast cancer patients treatment [10’]

Marek Kozicki (LUT, Lodz): Using 3D dosimetry in radiotherapy: DosLab-Poland experience [15’]

Krzysztof Ślosarek (IO, Gliwice): Planning, verification and realization of gated VMAT technique
[15’]

Paulina Leszczyńska (IO, Gliwice): Physical aspect of total marrow irradiation (TMI) [10’]
11:30 – 12:00
Coffee Break (and poster viewing)
12:00 – 13.00
Particle Therapy (Part 2)
 Xun Jia (UTSW, Dallas): Fast Monte Carlo simulation on GPU platform for particle therapy [30’]

Paweł Olko (IFJ, Kraków): Cooperation towards the first patient on proton scanning beam at the
Bronowice Cyclotrone Centre [20’]

Tomasz Kajdrowicz (IFJ, Kraków): Collaborative network for particle therapy centers in Italy,
Poland, Austria, Czech Republic and Sweden (IPACS) on harmonization of modern proton therapy
[10’]
13:00 – 13.40

Radiation Biology and Biomarkers (Part 2)
Andrzej Gamian (WMU, Wrocław): Unconventional glycation products and their partially protective
activity against DNA damage in cells irradiated with X ray [20’]

Andrzej Dworak (CPCM, Zabrze): Nanocarriers of doxorubicin via thermally induced aggregation of
its polymeric conjugates [20’]
13.40 – 14:00
General conclusions and closing ceremony
14:00 –
Lunch
Poster Presentations

B. Biesaga, A. Mucha-Małecka, A. Janecka-Widła, S. Szostek, D. Słonina, A. Kowalczyk, K. Halaszka,
M. Przewoźnik: Prognostic significance of HPV16 presence, its load and genome status in patients with
squamous cell carcinoma of head and neck from Cracow area, Poland.

M. Ros-Mazurczyk, A. Wojakowska, L. Marczak, K. Polanski, M. Pietrowska, K. Jelonek, I. Dominczyk,
A. Hajduk, T. Rutkowski, K. Skladowski, P. Widlak: Ionizing radiation affects profile of serum metabolites:
increased level of 3-hydroxybutyric acid in serum of cancer patients treated with radiotherapy.

Ł. Boguszewicz, A. Hajduk, A. Skorupa, M Ciszek, J. Mrochem-Kwarciak, K. Składowski, M. Sokół: Early
treatment response detection in head and neck cancer patients by means of 1H NMR based metabolomic.

M. Pietrowska, S. Funk, M. Gawin, Ł. Marczak, P. Widłak, T. Whiteside: Molecular profiling of tumorderived exosomes in plasma of cancer patients.

A. Walaszczyk, M. Pietrowska, A. Wojakowska, A. Abramowicz, P. Rodziewicz, J. Polańska, K. Behrendt,
E. Nowicka, R. Tarnawski, P. Widłak: Identification of serum proteins associated with the risk of
metastasis of breast cancer patients.

K. Szoltysek, P. Janus, A. Walaszczyk, T. Stokowy, P. Widlak: Interplay of NF-kB- and p53-dependent
signaling pathways in cellular response to ionizing radiation.

E. Wolny-Rokicka, J. Wydmański, A. Tukiendorf: Comparison and estimate of the prognostic value of
lipids profiles in 2 groups of patients with prostate cancer in depends on advancement.

E. Wolny-Rokicka, J. Wydmański, A. Tukiendorf, P. Mróz, A. Namysł-Kaletka, K. Gramacka,
J. Lipiński: Correlating parameters platelet counts (PLT) and mean platelet volume (MPV) with tumor and
possibility finding his threshold of size.

J. Mrochem-Kwarciak, T. Rutkowski, A. Wygoda, R. Deja, Ł. Boguszewicz, P. Widłak, K. Składowski:
Osteopontin (OPN) as an instant, predictive biomarker of tumor hypoxia and distant dissemination of
HNSCC in patients treated by radiation and chemotherapy.

A. Abramowicz, I. Tinhofer-Keilhol, P. Widlak, M. Pietrowska: FaDu-derived radiochemotherapy-resistant
clonal cell lines as an experimental model system in exosome research: preliminary study.

P. Polanowski, J. Wydmanski, A. Tukiendorf, B. Masłyk: Radiation-induced injury of the exocrine pancreas
after chemoradiotherapy for gastric cancer.

T. Krzysztofiak, W. Majewski: The efficacy of radical radiotherapy for patients with primarily diagnosed
prostate cancer with metastases to regional lymph nodes.

H. Grzbiela, M. Stąpór-Fudzińska, R. Tarnawski: The efficacy and safety of stereotactic radiation therapy
in patients with multiple intracranial meningiomas - a case report.

M. Gawkowska, E. Chmielik, A. d' Amico, W. Bal, E. Nowicka, B. Bobek-Bilewicz, R. Tarnawski:
Somatostatin receptor scintigraphic imagining and clinical decision making in advanced
esthesioneuroblastoma.

E. Nowicka, M. Gawkowska, W. Bal, M. Jarząb, H. Grzbiela, B. Bobek- Billewicz, R. Tarnawski: Unusual
presentation of dissemination via cerebrospinal fluid in malignant gliomas-the Centre of Oncology Institute
Gliwice experience.

E. Nowicka, M. Gawkowska, W. Bal, M. Jarząb, H. Grzbiela, B. Bobek- Billewicz, R. Tarnawski: The
feasibility of reirradiation using intensity-modulated radiation in selected patients with recurrent gliomas.

K. Dębiec, I. Gorczewska, P. Leszczyńska, K. Gorczewski, W. Leszczyński, M. Kalemba, J. Wydmański:
Evaluation of the 18-FDG-PET/CT in radiotherapy planning for unresectable or inoperable gastric cancer
patients.

B. Jochymek, L. Miszczyk: Half-body irradiation as palliative treatment of patients with multiple painful
bone metastases with application tomotherapy.

E. Wolny-Rokicka, A. Tukiendorf, J. Wydmański, D. Roszkowska, B. Staniul: Thyroid function after
postoperative radiation therapy in patients with breast cancer.

D. Księżniak-Baran, M. Stankiewicz, K. Hasse-Lazar, S. Blamek: Linac–based stereotactic radiotherapy
as a salvage treatment in patients with Cushing’s disease. Is there a chance for achieving hormonal
control?

K. Szczepanik, M. Stąpór-Fudzińska, D. Bodusz , B. Jochymek , E. Telka, L. Miszczyk:.Detection of the
GoldAnchor™ markers implanted in the liver by the CyberKnife system during the real-time image-guided
robotic radiotherapy of patients with liver metastases.

Z. Wygoda, D. Handkiewicz-Junak, J. Krajewska, B. Jarząb: Assessment of radiotherapy effects in
treatment of anaplastic thyroid carcinoma.

W. Osewski, Ł. Dolla, R. Kulik, K. Ślosarek: Dose distribution reconstruction for gated VMAT technique.

I. Brąclik, W. Osewski, K. Ślosarek: Dose distribution deformation based on deformable registration.

M. Pelak, K. Dębiec: Virtual versus conventional radiotherapy simulation: a single institution experience
report.

A. Skorupa, M. Kozicki, P. Maras, M. Ciszek, Ł. Boguszewicz, M. Sokół: Application of high field MR
micro-imaging in polymer gel dosimetry – preliminary results.

A. d'Amico, O. Chrabański, I. Gorczewska, M. Zieliński: Triphasic [18F]-Fluorodeoxyglucose CT-PET in
the differential diagnosis of lung nodules and mediastinal lymph nodes: initial results.

B. Niewiadomska, A. Bekman, A. Woźnica, Ł. Dolla, S. Blamek: Measurement of dose in the environment
of cardiovascular implantable electronic devices (CIEDs) for prostate cancer patients treated by
Tomotherapy.

S. Blamek, M.Tajstra, E. Gadula-Gacek, D. Gabryś, B. Niewiadomska, A. Bekman, Ł. Dolla,
M. Gąsior, P. Marczyński: Implantable cardioverters-defibrillators and cardiac resynchronization therapy –
defibrillator devices in the setting of helical Tomotherapy: an in vitro study.

L. Stolarczyk, J. Gajewski, M. Kłodowska, W. Komenda, D. Krzempek, J. Kunst, N. Mojżeszek, M. Liszka,
A. Pędracka, M. Rydygier, B. Sadowski, U. Sowa, P. Olko: Commissioning of spot scanning proton
therapy system in Cyclotron Center Bronowice.

M. Liszka, M. Rydygier, B. Sadowski, A. Pędracka, W. Komenda, L. Stolarczyk, P. Olko: Feasibility study
of patient plan verification method for scanning proton beam at the IFJ in Krakow, Poland.

T. Horwacik, B. Michalec, L. Grzanka, E. Durlak, E. Ogrodowicz, T. Nowak: Commissioning of the new
ocular proton radiotherapy facility at the CCB IFJ PAN.

U. Sowa, T. Nowak, T. Horwacik, T. Kajdrowicz: Application of wedges in the eye line treatment facility in
the IFJ CCB Kraków.

A. Pędracka, L. Stolarczyk, M. Liszka, W. Komenda, B. Sadowski, K. Skowrońska, P. Olko: Dosimetric
verification of treatment planning system in proton spot scanning pencil beam radiotherapy.

G. Mierzwińska, B.Michalec, B. Sadowski, M. P.R. Waligórski: Alanine-based QA protocol for dose
assessment in ocular melanoma proton radiotherapy.

J. Gajewski, M. Bednarczyk, K. Skowrońska, L. Stolarczyk, T. Kajdrowicz, P. Olko: Machine log file
analysis as a part of treatment Quality Assurance with proton scanning beams.